secwatch.observer — SEC 8-K summary ====================================== Issuer: TANDEM DIABETES CARE INC (TNDM) CIK: 0001438133 Form: 8-K Filed at: 2026-11-13T13:35:29+00:00 Accession: 0001438133-26-000148 Event type: regulatory Sentiment: positive Materiality: 0.65 Item codes: 8.01 LLM model: deepseek-v4.1-flash:cloud@v2 Tandem wins FDA 510(k) clearance for tubeless Tandem Mobi insulin pump; US launch planned for H1 2027 -------------------------------------------------------------------------------- - FDA granted 510(k) clearance on November 12, 2026 for Tandem Mobi as a tubeless automated insulin delivery system. - New tubeless cartridge and infusion set converts the existing Tandem Mobi pump; infusion set cleared for up to 7 days of wear, cartridge for 3 days of use. - Mobi keeps Control-IQ+ hybrid closed-loop technology and is now cleared for both tubeless and tubed infusion, which Tandem calls the only pump offering both options. - Full US commercial launch of the tubeless cartridge and infusion set is planned for the first half of 2027. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813326000148/0001438133-26-000148-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1438133/000143813326000148/tndm-20261112.htm HTML page: https://secwatch.observer/filing/0001438133-26-000148 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer